ClinicalTrials.gg
CompletedNCT04919291Updated Jun 9, 2021

Direct Comparison of TG and WFO LASIK

An interventional study of Topoguided LASIK and Wavefront optimized LASIK in Keratomileusis, Laser In Situ and Contrast Sensitivity, sponsored by Taipei Nobel Eye Clinic. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Taipei Nobel Eye Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Sep 2019, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

To compare the efficacy to different profiles, direct head-to-head studies had been conducted. In one previous review study revealed that TG LASIK provided patient with better uncorrected visual acuity (UCVA) than WFO LASIK and WFG LASIK. In recent previous contralateral eye studies also showed that TG LASIK induced less postoperative higher-order aberration than WFO LASIK. However, these studies included only low-to-moderate myopia patients, for patients with high myopia (spherical equivalent > 6D), the effect of TG LASIK comparing with WFO LASIK had not been reported before.

The aim of our study is to analyze and compare the visual performance of TG LASIK and WFO LASIK in high myopia and low-to-moderate myopia patients, , particularly UCVA, corrected distance visual acuity (CDVA), contrast sensitivity (CS), and wavefront aberration.

02

Conditions studied

  • Keratomileusis, Laser In Situ
  • Contrast Sensitivity
03

In context

Lead sponsor

Taipei Nobel Eye Clinic is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 20 and 50 years old
  • CDVA of both eyes could reach 0.1 logarithm of the minimum angle of resolution (logMAR)
  • stable refractive errors of myopia and astigmatism

Exclusion criteria

Exclusion Criteria:

  • cataract
  • corneal opacities or irregularities
  • dry eye (Schirmer's test I ≤ 5mm)
  • amblyopia
  • coexisting ocular pathologies
  • glaucoma
  • non-dilating pupil
  • history of intraocular surgery, laser therapy, or retinopathy
  • optic nerve or macular diseases
  • estimated postoperative cornea residual stromal thickness less than 250 μm
  • pregnancy or under lactation
  • uncontrolled diabetic mellitus or systemic immune disease
  • refusal or unable to maintain follow-up
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Active comparator
    Topoguided LASIK

    Topoguided ablation profile on dominant eye

    Device: Topoguided LASIK

  • Active comparator
    Wavefront optimized LASIK

    Wavefront optimized ablation profile on non-dominant eye

    Device: Wavefront optimized LASIK

Interventions

  • DeviceTopoguided LASIK

    Topoguided ablation profile on dominant eye

  • DeviceWavefront optimized LASIK

    Wavefront optimized ablation profile on non-dominant eye

06

What researchers measure

Primary outcomes

  1. Visual acuity

    uncorrected visual acuity and corrected distance visual acuity

    Time frame: 3 months after surgery

  2. Corneal wavefront analysis

    horizontal coma aberration (Z 3,1), spherical aberration (Z 4,0), and trefoil aberration

    Time frame: 3-months postoperative visit

  3. Contrast sensitivity

    4 spatial frequencies: 3, 6, 12, and 18 cycles per degree (cpd).

    Time frame: 3-months postoperative visit

  4. Quality of vision questionnaire

    A 11-item questionnaire, item scores range from 0 to 10 and higher item scores in questionnaire indicated more difficulty in achieving specific visual tasks

    Time frame: 3-months postoperative visit

07

Study locations

1 site
  • Taipei Nobel Eye Clinic
    Taipei, Taiwan
08

References and documents

Publications

  • Sutton G, Lawless M, Hodge C. Laser in situ keratomileusis in 2012: a review. Clin Exp Optom. 2014 Jan;97(1):18-29. doi: 10.1111/cxo.12075. Epub 2013 Jun 21. PubMed 23786377 ↗
  • Moreno-Barriuso E, Lloves JM, Marcos S, Navarro R, Llorente L, Barbero S. Ocular aberrations before and after myopic corneal refractive surgery: LASIK-induced changes measured with laser ray tracing. Invest Ophthalmol Vis Sci. 2001 May;42(6):1396-403. PubMed 11328757 ↗
  • Schallhorn SC, Farjo AA, Huang D, Boxer Wachler BS, Trattler WB, Tanzer DJ, Majmudar PA, Sugar A; American Academy of Ophthalmology. Wavefront-guided LASIK for the correction of primary myopia and astigmatism a report by the American Academy of Ophthalmology. Ophthalmology. 2008 Jul;115(7):1249-61. doi: 10.1016/j.ophtha.2008.04.010. PubMed 18598819 ↗
  • Stonecipher K, Parrish J, Stonecipher M. Comparing wavefront-optimized, wavefront-guided and topography-guided laser vision correction: clinical outcomes using an objective decision tree. Curr Opin Ophthalmol. 2018 Jul;29(4):277-285. doi: 10.1097/ICU.0000000000000495. PubMed 29787391 ↗
  • Kim J, Choi SH, Lim DH, Yang CM, Yoon GJ, Chung TY. Topography-guided versus wavefront-optimized laser in situ keratomileusis for myopia: Surgical outcomes. J Cataract Refract Surg. 2019 Jul;45(7):959-965. doi: 10.1016/j.jcrs.2019.01.031. Epub 2019 Jun 10. PubMed 31196580 ↗
  • Kim J, Choi SH, Lim DH, Yoon GJ, Chung TY. Comparison of outcomes after topography-modified refraction versus wavefront-optimized versus manifest topography-guided LASIK. BMC Ophthalmol. 2020 May 14;20(1):192. doi: 10.1186/s12886-020-01459-0. Erratum In: BMC Ophthalmol. 2020 Dec 29;20(1):492. doi: 10.1186/s12886-020-01753-x. PubMed 32410588 ↗
  • Ozulken K, Yuksel E, Tekin K, Kiziltoprak H, Aydogan S. Comparison of Wavefront-Optimized Ablation and Topography-Guided Contoura Ablation With LYRA Protocol in LASIK. J Refract Surg. 2019 Apr 1;35(4):222-229. doi: 10.3928/1081597X-20190304-02. PubMed 30984979 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Mar 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Jun 9, 2021
StartActual
Sep 26, 2019
Primary completionActual
Mar 14, 2020
CompletionActual
Jun 30, 2020
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04919291
Lead sponsor
Taipei Nobel Eye Clinic
Responsible party
Chao-Kai Chang (Dean, Nobel Eye Institute, Taipei Nobel Eye Clinic) — Principal investigator
First posted
Jun 9, 2021
Start date
Sep 26, 2019
Primary completion
Mar 14, 2020
Completion
Jun 30, 2020
Last update
Jun 9, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion